EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Food oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?

Sanem Eren Akarcan, Handan Duman Şenol, Figen Gülen, Esen Demir

Allergologia et Immunopathologia · 2023

DOI: 10.15586/aei.v51i6.907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergologia et Immunopathologia, 2023. Verfasst von Sanem Eren Akarcan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tepecik Training and Research Hospital, Pediatric Allergy and Immunology Clinic, İzmir, Turkiye; saneren@yahoo.com. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Food Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral immunotherapy (OIT) has gained popularity recently for IgE-mediated food allergy. Omalizumab (OMZ) has been used in patients (10–20%) who have too severe/frequent allergic reactions (AR) to continue OIT, to reduce these reactions. In this study, it was aimed to compare two groups of patients who completed OIT with and without OMZ and to seek determinants predicting the need of this treatment. It was also aimed to share the clinical findings regarding the long-term use of OMZ and the withdrawal process. Forty-one patients were started OIT and 93% could be desensitized. Two groups were similar in means of demographic characteristics, and clinical and laboratory findings. The patients who needed OMZ during OIT had also lower reaction doses during oral challenge (p = 0.037). Higher AR rate in this group declined after starting OMZ (p < 0.001). The injection intervals of OMZ were gradually extended. Most patients were able to discontinue OMZ (81%). There were no severe reactions during drug withdrawal attempts. The low reaction thresholds during oral food challenge may give a clue about OMZ requirement during OIT. It may be an option to start the treatment before OIT if reaction was seen in the first few steps of the oral food challenge. For the sake of safety, extension of injection intervals should be preferred instead of abruptly stopping OMZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicFood HypersensitivityHumansAdministration, OralOmalizumabAllergensImmunosuppressive AgentsAntibodies, Anti-Idiotypic

Stichwörter der Autor:innen

allergic reactionsfood allergyfood challenge testomalizumaboral immunotherapy

Substanzen

OmalizumabAllergensImmunosuppressive Agentsanti-IgE antibodiesAntibodies, Anti-Idiotypic

Autor:innen und Institutionen

  • Tepecik Training and Research Hospital, Pediatric Allergy and Immunology Clinic, İzmir, Turkiye; saneren@yahoo.com.
  • Ege University Faculty of Medicine, Department of Pediatric Allergy and Immunology, İzmir, Turkiye.

Zitieren

APA

Akarcan, S. E., Şenol, H. D., Gülen, F., & Demir, E. (2023). Food oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v51i6.907

Vancouver

Akarcan SE, Şenol HD, Gülen F, Demir E. Food oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?. Allergologia et Immunopathologia. 2023. doi:10.15586/aei.v51i6.907

BibTeX
@article{Akarcan2023,
  author = {Akarcan, Sanem Eren and Şenol, Handan Duman and Gülen, Figen and Demir, Esen},
  title = {Food oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?},
  journal = {Allergologia et Immunopathologia},
  year = {2023},
  doi = {10.15586/aei.v51i6.907}
}
Kostenlos starten →